Randomized, Double-Blind, Placebo-Controlled Trial of ID-CBT5101, a Tyndallized Clostridium butyricum Postbiotic, in Adults with Mild-to-Moderate Knee Osteoarthritis
Journal of Microbiology and Biotechnology · 2026
DOI: 10.4014/jmb.2512.12024 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Microbiology and Biotechnology, 2026. Verfasst von Han Bin Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Ildong Bioscience, Pyeongtaek-si 17957, Republic of Korea. Hauptthemen laut MEDLINE: Clostridium butyricum, Osteoarthritis, Knee, Probiotics. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Osteoarthritis (OA) is a common cause of chronic pain and functional impairment in older adults. Evidence suggests a gut-joint axis, where gut dysbiosis and systemic low-grade inflammation may contribute to OA pathogenesis. Postbiotics, which are non-viable microbial products such as heat-killed bacteria, have been proposed as safe and stable alternatives to live probiotics. ID-CBT5101, a tyndallized Clostridium butyricum preparation, reduced inflammation and preserved cartilage in a rat OA model. We conducted a 12-week randomized, double-blind, placebo-controlled trial to assess ID-CBT5101 safety and efficacy in adults with mild-to-moderate knee OA. Ninety-six participants were randomized to receive either ID-CBT5101 (1.0 × 1010 CFU-equivalents/day) or placebo. The primary endpoint was the change from baseline in walking pain on a 100-mm visual analog scale (VAS). Secondary outcomes included WOMAC, Korean Knee Score (KKS), patient global assessment, and serum biomarkers. Both groups showed significant within-group improvements in VAS, WOMAC, and KKS over 12 weeks. However, no significant differences were observed between groups for any clinical endpoint. Serum interleukin-6 (IL-6), cartilage oligomeric matrix protein (COMP), prostaglandin E2 (PGE2), leukotriene B4 (LTB4), transforming growth factor-β (TGF-β), and high-sensitivity C-reactive protein (hs-CRP) showed no consistent changes favoring ID-CBT5101. Safety profiles were comparable between groups, with no treatment-related adverse events. ID-CBT5101 was safe and well-tolerated, but it did not demonstrate significant clinical efficacy compared with placebo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ildong Bioscience, Pyeongtaek-si 17957, Republic of Korea.
- Ildong Pharmaceutical Co., Ltd., Seoul 06752, Republic of Korea.
- Department of Microbiology, College of Medicine, Dongguk University, Gyeongju 38066, Republic of Korea.
- School of Food Science and Biotechnology, Food and Bio-industry Institute, Kyungpook National University, Daegu 41566, Republic of Korea.
Zitieren
APA
Lee, H. B., Lee, J., Jeong, K., Yang, J., Jung, Y. H., & Moon, J. S. (2026). Randomized, Double-Blind, Placebo-Controlled Trial of ID-CBT5101, a Tyndallized Clostridium butyricum Postbiotic, in Adults with Mild-to-Moderate Knee Osteoarthritis. Journal of Microbiology and Biotechnology. https://doi.org/10.4014/jmb.2512.12024
Vancouver
Lee HB, Lee J, Jeong K, Yang J, Jung YH, Moon JS. Randomized, Double-Blind, Placebo-Controlled Trial of ID-CBT5101, a Tyndallized Clostridium butyricum Postbiotic, in Adults with Mild-to-Moderate Knee Osteoarthritis. Journal of Microbiology and Biotechnology. 2026. doi:10.4014/jmb.2512.12024
BibTeX
@article{Lee2026,
author = {Lee, Han Bin and Lee, Jinho and Jeong, Kyuho and Yang, Jungwoo and Jung, Young Hoon and Moon, Jin Seok},
title = {Randomized, Double-Blind, Placebo-Controlled Trial of ID-CBT5101, a Tyndallized Clostridium butyricum Postbiotic, in Adults with Mild-to-Moderate Knee Osteoarthritis},
journal = {Journal of Microbiology and Biotechnology},
year = {2026},
doi = {10.4014/jmb.2512.12024}
}
EUVIMED